QC
OCUL icon

Quantessence Capital’s Ocular Therapeutix OCUL Stock Holding History

Quantessence Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,467
Closed -$106K – 272
2025
Q2 		$106K Buy
+11,467
New +$89.8K 0.03% 172

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Quantessence Capital's OCUL Position: Q3 2025 in Review

Quantessence Capital sold out of Ocular Therapeutix (OCUL) in Q3 2025, closing a stake of 11,467 shares — an estimated $106K sold.

Quantessence Capital first reported a position in OCUL in Q2 2025 and held it in 1 quarter. The position peaked at $106K in Q2 2025. 216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Quantessence Capital reported no remaining Ocular Therapeutix position as of Q3 2025 after selling out during the quarter.
  • Quantessence Capital sold 11,467 Ocular Therapeutix shares in Q3 2025, an estimated $106K.
  • Quantessence Capital first reported a position in Ocular Therapeutix in Q2 2025 and held it in 1 quarter.
  • Quantessence Capital's Ocular Therapeutix position peaked at $106K in Q2 2025.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.